The Food and Drug Administration’s polarizing vaccine chief is leaving the agency after a brief tenure that drew the ire of ...

Under the Inflation Reduction Act, medications with the same active ingredient will be treated as the same drug for price ...

It's shaping up to be a big year for Boehringer Ingelheim—at least if the FDA plays ball. | Boehringer Chief Medical Officer Lykke Hinsch Gylvin, M.D., set out the German drugmaker's plans to launch ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

WASHINGTON - It probably sits waiting, largely unnoticed, on the shelves of every smoke shop, convenience store and gas ...

Strong performance and sales acceleration with total net sales of CHF 58 million in H1 2025 and increase of 145% compared to ...

In a legal opinion, Mississippi’s attorney general stated it is illegal to sell hemp products that are not approved by the ...

Arquitos Capital Management gained 13.1% in Q2 2025. Learn how they turned market uncertainty into opportunity with Liquidia ...

Operator: Thank you for standing by, and welcome to the Kiniksa Pharmaceutical Second Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, today ...

Shares of drugmaker Sarepta Therapeutics surged in afterhours trading Monday after the company said it would resume shipping its gene therapy.

Regenerative Solutions revenue up 41% with Integrity™ Implant System ahead of expectations and continued strong Hyalofast® ...

Some of the experimental treatments require maintenance in the form of surgery and additional follow-up care, leaving many ...